Trial Profile
A Multi-Center, Multinational, Randomized, Double-Blind, Study to Evaluate the Efficacy and Safety of Belimumab (HGS1006) in Combination with Azathioprine for the Maintenance of Remission in Wegener's Granulomatosis and Microscopic Polyangiitis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 25 Aug 2023
Price :
$35
*
At a glance
- Drugs Belimumab (Primary) ; Azathioprine
- Indications Granulomatosis with polyangiitis; Microscopic polyangiitis
- Focus Registrational; Therapeutic Use
- Acronyms BREVAS
- Sponsors Human Genome Sciences
- 22 Jan 2019 Results published in the Arthritis and Rheumatology
- 16 Jun 2018 Results assessing effects on Biomarkers presented at the 19th Annual Congress of the European League Against Rheumatism
- 08 Nov 2017 Primary endpoint (Time to first relapse) has not been met, according to the results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting